US Stock MarketDetailed Quotes

ARCT Arcturus Therapeutics

Watchlist
  • 15.480
  • +0.640+4.31%
Close Dec 20 16:00 ET
  • 15.480
  • 0.0000.00%
Post 16:13 ET
419.31MMarket Cap-6.64P/E (TTM)

Arcturus Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Arcturus Therapeutics Q3 2024 Earnings Date

Currency：USDNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
36.59M
41.67M
+5.08M
Beat Est.
-18.94%
-7.68%
+13.89%
EPS
-1.14
-0.26
+0.88
Beat Est.
-86.36%
+57.38%
+77.12%
Analyst Rating
Strong Buy

Dec 21, 2024

Arcturus Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 52.997M--
--2024/Q4-- / 45.917M--
Nov 7, 20242024/Q341.673M / 36.592M--
Aug 5, 20242024/Q249.859M / 22.234M--
May 8, 20242024/Q138.012M / 17.672M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 52.997M--
--2024/Q4-- / 45.917M--
Nov 7, 20242024/Q341.673M / 36.592M--
Aug 5, 20242024/Q249.859M / 22.234M--
May 8, 20242024/Q138.012M / 17.672M--

Unlock Free Earnings Estimates

Arcturus Therapeutics Earnings Reports

  • Arcturus Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 7 17:08 ET

  • Arcturus Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 5 16:53 ET

  • Arcturus Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 8 17:08 ET

  • Arcturus Therapeutics | 10-K: FY2023 Annual Report

    Mar 14 09:14 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Ermenegildo Zegna NV
    ZGN
    +6.16%
    DexCom
    DXCM
    +5.57%
    New Fortress Energy
    NFE
    +5.37%
    Workday
    WDAY
    +2.33%
    eBay
    EBAY
    +1.66%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 21, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data